Navigation Links
Uroplasty Reports Third Quarter Fiscal 2009 Results
Date:2/3/2009

actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that our SUmiT clinical trial will produce favorable results, that even if it does produce favorable result third-party payors will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses, or that we will timely obtain, or even succeed at all at obtaining, a specific "listed" CPT reimbursement code from the AMA for Urgent PC treatments. We further cannot assure that reimbursement or other issues will not further impact our fiscal 2009 results.

     For Further Information: Uroplasty, Inc.           EVC Group
     David Kaysen, President and CEO, or                Doug Sherk (Investors)
     Medi Jiwani, Vice President, CFO, and Treasurer,   415.896.6820
     952.426.6140                                       Chris Gale (Media)
                                                        646.201.5431



                       UROPLASTY, INC. AND SUBSIDIARIES

                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)

                            Three Months Ended       Nine Months Ended
                               December 31,              December 31,
                            2008         2007         2008         2007

    Net sales           $3,387,285   $3,729,314  $11,833,422   $9,717,531
    Cost of goods sold     533,987      789,955    1,791,153    2,053,208

    Gross profit         2,853,298    2,939,359   10,042,269    7,664,323

    Operating expenses
      General and
       administrative      713,545      799,193    2,670,653    2,755,000
      Research and
       development         723,673      460,374    1,457,170    
'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... 2014 Research and Markets has announced ... 2014-2018" report to their offering. ... a technique used to determine the size of a particle ... crucial to analyze the size of particles as it can ... is performed to determine the behavior and nature of a ...
(Date:7/25/2014)... in each person,s digestive tract. Scientists believe that some ... harmful infections, but their role in human health is ... the role of these bacteria, a team of researchers ... fluctuations in the bacterial populations of two research subjects ... July 25 issue of the journal Genome Biology ...
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2
... Authorities to Launch Final ... Clinical Trial for Asacard(R), NEW ... appointment of Dr. Geert Cauwenbergh as Chief Executive,Officer. Dr. Cauwenbergh ... assisting RHEI Pharmaceuticals since August 1, 2008,in providing the necessary ...
... (IPM) today announced it was named to Inc. ... companies nationwide for a second consecutive year. The ... broad range of industries, helping companies operate more ... one of the Chicago area’s top 100 businesses, ...
... Mymetics,Corporation (OTCBB:MYMX) announced today that its ... & Poor,s Market Access Program, an,information distribution ... have their company information disseminated to users ... information to be made,available through this program ...
Cached Biology Technology:RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 2RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 3RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 4 Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area 2Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program 2
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... Barts Cancer Institute have found that targeting a molecule ... effective, according to research published in Nature ... of Queen Mary University of London, have found that ... body to repair itself after chemotherapy or radiotherapy, which ... removed FAK from blood vessels that grew in melanoma ...
(Date:7/25/2014)... 100,000s of people lived on the land now called ... control the availability of plants they used for food, ... fire to maintain desired habitat and natural resources. , ... Pacific Southwest Station, will lead a field trip ... the Ecological Society of America,s 99th Annual Meeting, in ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... Calif., Jan. 10, 2011 Based on its ... Frost & Sullivan recognizes Cardiocom with the 2011 ... Technology. Cardiocom provides integrated clinical telehealth services that ... (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) ...
... Dry Copper Kills Bacteria on Contact ... their populations, according to a paper in the February ... Microbiology . They do so literally in minutes, by ... says the study,s corresponding author, Gregor Grass of the ...
... China, Feb. 1, 2011/PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group ... ) ("Weikang" or the "Company"), a leading developer, ... Western prescription and OTC pharmaceuticals and other health ... China, today announced the completion of its private ...
Cached Biology News:Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4Tips from the journals of the American Society for Microbiology 5Tips from the journals of the American Society for Microbiology 6Tips from the journals of the American Society for Microbiology 7Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
... Hot Start Taq Monoclonal ... before the onset of ... amplification and primer-dimer formation. ... raised, the antibody is ...
... Workstation brings together UV irradiation and antimicrobial ... against PCR contamination! Quickly inactivate DNA ... a clean environment with antimicrobial coated stainless ... within minutes with built-in 30-minute timer ...
... The flexible and easy ... used to control all members ... family. It features a clear ... visual assay setup, user-friendly and ...
Biology Products: